In vivo efficacy of PHA-739358 on human leukemia cells. Pt2 cells (2x106) were transplanted in NSG mice, which were started on treatment on day 7 with three cycles of PHA-739358. (A). Representative example of flow cytometry analysis of the human ALL cells (CD10+CD19+) in peripheral blood at different time points. (B). Bar graph representing the percentage of CD10+CD19+ cells in peripheral blood (n = 8). (C). Survival of mice in PHA-739358 group (n = 8, 30 mg/kg, iv, qd, 7 days on/7 days off x 3 cycles) was significantly prolonged compared to the vehicle treatment group (n = 8) (p = 0.0002). (D). Weights of spleens of vehicle treatment group compared to those of PHA-739358 treatment group (p < 0.001). (E). Weights loss or gain of mice during treatment.